Home > Insider Trading > Filing (0000903423-14-000074)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1457612	Genocea Biosciences Inc.	GNCA	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1131399	Plc Glaxosmithkline	980 Great West Road Brentford Middlesex X0 TW8 9GS		No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-10	143,773	$12.00	143,773	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2014-02-10	775,694	$0.00	919,467	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-02-10	344,473	$0.00	1,263,940	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-02-10	407,727	$0.00	1,671,667	No	4	C	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-02-10	9,230,769	$0.00	775,694	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-10	4,099,231	$0.00	344,473	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-02-10	4,851,958	$0.00	407,727	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Shares issued upon the closing of the Issuer's initial public offering at the initial public offering price of $12.00 per share.
Shares are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.
The shares of Series A Preferred Stock converted automatically into Common Stock, on a 1-for-11.9 basis, upon the closing of the Issuer's initial public offering on February 10, 2014, and had no expiration date.
The shares of Series B Preferred Stock, including all accrued cumulative and unpaid dividends thereon, converted automatically into Common Stock, on a 1-for-11.9 basis, upon the closing of the Issuer's initial public offering on February 10, 2014, and had no expiration date.
The shares of Series C Preferred Stock converted automatically into Common Stock, on a 1-for-11.9 basis, upon the closing of the Issuer's initial public offering on February 10, 2014, and had no expiration date.